News and Trends 15 Aug 2022
Aptinyx fibromyalgia drug misses endpoint
Biopharma company Aptinyx Inc. says its phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia did not achieve statistically significant separation from placebo on the study’s…